Cytosorbents (CTSO) to Release Earnings on Monday

Cytosorbents (NASDAQ:CTSO) is expected to post its quarterly earnings results after the market closes on Monday, March 31st. Analysts expect Cytosorbents to post earnings of ($0.07) per share and revenue of $10.09 million for the quarter. Investors interested in registering for the company’s conference call can do so using this link.

Cytosorbents Stock Performance

CTSO stock opened at $1.00 on Friday. The firm has a 50 day moving average of $1.07 and a two-hundred day moving average of $1.05. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The company has a market capitalization of $54.68 million, a price-to-earnings ratio of -2.78 and a beta of 0.78. The company has a quick ratio of 1.58, a current ratio of 1.97 and a debt-to-equity ratio of 1.06.

Analysts Set New Price Targets

CTSO has been the subject of a number of recent research reports. StockNews.com assumed coverage on shares of Cytosorbents in a report on Wednesday. They issued a “hold” rating for the company. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a research note on Tuesday, February 25th. Two research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.67.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.